Milestone Monday: The Starting Gun Is Not The Finish Line
Biopharma’s US IPO class of 2026 has reached 26 and raised $8.19bn, but offerings are shrinking and many new listings have slipped below their IPO prices. Iovance shows what a strong run looks like, while the year’s biggest decliners show who hit the wall.
Milestone Monday: Signed, Sealed, Disappointed
Servier paid about 58% of the maximum price before the pivotal data arrived. This week’s deals show what upfront money secures and what it doesn’t.
Milestone Monday: How Two Very Large Parties Helped Biotech’s IPO Year Reach $8.89bn
The count is far from 2021’s 107, but this year’s $306.6m average is the highest of the past seven years. Bambusa and Aspen, the latest two, came in under it.
Milestone Monday: Biopharma IPOs Are Playing To A Friendly House
More from this edition
Milestone Monday: The Weekend Madrid Stood Up For Small Cell Lung Cancer
Milestone Monday: The Renewal And The Revolution
Milestone Monday: At BIO 2026, The Sellers Set The Pace
Money is everywhere and buyers are hungry, so biotechs are seeing several suitors at once and in no rush to commit. The complications: the most wanted assets keep turning up in China, and a US pricing rule means no deal abroad stays abroad.